Jefferies Group Increases Catalent Inc. (CTLT) Price Target to $28.00
Catalent Inc. (NYSE:CTLT) had its target price hoisted by investment analysts at Jefferies Group from $25.00 to $28.00 in a note issued to investors on Thursday. The brokerage presently has a “hold” rating on the stock. Jefferies Group’s price target would suggest a potential upside of 8.36% from the company’s previous close.
Other research analysts have also issued reports about the company. Bank of America Corp. raised Catalent from a “neutral” rating to a “buy” rating in a research report on Monday, June 20th. Wells Fargo & Co. raised Catalent from a “market perform” rating to an “outperform” rating in a research report on Tuesday, June 21st. One investment analyst has rated the stock with a sell rating, five have assigned a hold rating and four have assigned a buy rating to the stock. The stock has a consensus rating of “Hold” and an average price target of $27.83.
Shares of Catalent (NYSE:CTLT) opened at 25.84 on Thursday. The stock has a 50 day moving average price of $25.22 and a 200 day moving average price of $25.66. Catalent has a 12-month low of $18.92 and a 12-month high of $32.24. The stock has a market capitalization of $3.22 billion, a P/E ratio of 29.03 and a beta of 1.41.
Institutional investors have recently bought and sold shares of the company. M&T Bank Corp bought a new position in shares of Catalent during the first quarter worth approximately $207,000. Forward Management LLC increased its position in shares of Catalent by 8.7% in the first quarter. Forward Management LLC now owns 17,656 shares of the company’s stock worth $471,000 after buying an additional 1,411 shares during the last quarter. Royal Bank of Canada increased its position in shares of Catalent by 81.5% in the first quarter. Royal Bank of Canada now owns 34,988 shares of the company’s stock worth $933,000 after buying an additional 15,706 shares during the last quarter. Envestnet Asset Management Inc. increased its position in shares of Catalent by 45.2% in the first quarter. Envestnet Asset Management Inc. now owns 38,974 shares of the company’s stock worth $1,039,000 after buying an additional 12,141 shares during the last quarter. Finally, UBS Group AG increased its position in shares of Catalent by 1.1% in the first quarter. UBS Group AG now owns 66,308 shares of the company’s stock worth $1,769,000 after buying an additional 712 shares during the last quarter. Institutional investors and hedge funds own 99.72% of the company’s stock.
Catalent Company Profile
Catalent, Inc is a provider of advanced delivery technologies and development solutions for drugs, biologics and consumer health products. The Company’s segments include Oral Technologies, Medication Delivery Solutions, and Development and Clinical Services. The Oral Technologies segment provides advanced oral delivery technologies, including formulation, development and manufacturing of oral dose forms for prescription and consumer health products across all phases of a molecule’s lifecycle.
Receive News & Stock Ratings for Catalent Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalent Inc. and related stocks with our FREE daily email newsletter.